Published in Br J Cancer on June 01, 1998
International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood (1995) 1.08
Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol (1990) 1.05
Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry (1993) 1.04
Non-Hodgkin lymphoma. Multivariate analysis of prognostic factors including fraction of S-phase cells. Acta Oncol (1987) 0.97
DNA flow cytometry of follicular non-Hodgkin's lymphoma. J Clin Pathol (1991) 0.97
Flow cytometric DNA analysis: a prognostic tool in non-Hodgkin's lymphoma. Leuk Res (1989) 0.93
Prognostic value of DNA/RNA flow cytometry of B-cell non-Hodgkin's lymphoma: development of laboratory model and correlation with four taxonomic systems. Ann N Y Acad Sci (1986) 0.84
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
[Treatment with growth factors and cytokines in hematologic diseases]. Tidsskr Nor Laegeforen (1996) 2.03
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
Tissue specific expression and cDNA structure of a human transcript encoding a nucleic acid binding [oligo(dC)] protein related to the pre-mRNA binding protein K. Nucleic Acids Res (1994) 1.43
Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer (1993) 1.39
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol (1995) 1.16
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med (1993) 1.12
Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res (1996) 1.08
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol (1990) 1.07
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer (2004) 1.05
Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells. J Biol Chem (1992) 1.05
Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol (1991) 1.04
Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol (1999) 1.03
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
A new method for detachment of Dynabeads from positively selected B lymphocytes. J Immunol Methods (1992) 1.01
A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes. Blood (2000) 1.00
A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett (1997) 0.99
Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol (1996) 0.96
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival. Scand J Haematol (1985) 0.96
Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow. Blood (2000) 0.96
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer (1990) 0.96
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol (1981) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
The B cell antigen CD75 is a cell surface sialytransferase. J Exp Med (1990) 0.92
Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis. Proc Natl Acad Sci U S A (1994) 0.92
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer (1984) 0.92
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol (2001) 0.92
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer (1989) 0.91
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant (2005) 0.91
Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells (2000) 0.90
Thyroid antibodies in blood donors: prevalence and clinical significance. Acta Endocrinol (Copenh) (1984) 0.90
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Retinoblastoma protein is rapidly dephosphorylated by elevated cyclic adenosine monophosphate levels in human B-lymphoid cells. Cancer Res (1994) 0.88
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol (1986) 0.87
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87
Cellular antitumor immune response in women with risk factors for breast cancer. Cancer Res (1979) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol (2004) 0.87
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol (1999) 0.86
All-trans- and 9-cis-retinoic acid inhibit growth of normal human and murine B cell precursors. J Immunol (1995) 0.86
Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes. J Cell Physiol (1987) 0.86
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer (2004) 0.86
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol (1999) 0.86
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer (2000) 0.85
Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors. J Clin Invest (1994) 0.85
Cross-linking of CD53 promotes activation of resting human B lymphocytes. J Immunol (1994) 0.84
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens. Eur J Immunol (1989) 0.84
cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of cyclin D3 at the level of translation. Eur J Immunol (2000) 0.84
Involvement of ICE (Caspase) family in gamma-radiation-induced apoptosis of normal B lymphocytes. Scand J Immunol (1997) 0.84
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45). Scand J Immunol (1990) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Exp Cell Res (1999) 0.83
Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J (2012) 0.83
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer (2009) 0.83
c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization. Cytometry (1999) 0.83
A population-based study of spinal metastatic disease in South-East Norway. Clin Oncol (R Coll Radiol) (2009) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes. J Cell Physiol (1998) 0.83
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. J Immunol (1987) 0.83
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia (2006) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry. Acta Pathol Microbiol Scand A (1981) 0.83
Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood (1997) 0.82